Last reviewed · How we verify
Bismuth quadruple therapy
Bismuth quadruple therapy, marketed by Zhongda Hospital, is a combination treatment for H. pylori eradication that integrates bismuth subsalicylate, metronidazole, tetracycline, and a proton pump inhibitor. Its key strength lies in its multi-target approach, which effectively inhibits bacterial growth and reduces gastric acid secretion, potentially offering higher efficacy compared to triple therapy and other regimens. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Bismuth quadruple therapy |
|---|---|
| Also known as | pantoprazole, bismuth subcitrate, tetracycline, metronidazole, 10-day Bismuth quadruple therapy |
| Sponsor | Zhongda Hospital |
| Drug class | Antibacterial combination therapy |
| Target | Helicobacter pylori |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Drug interactions
- Warfarin
- Alcohol
Key clinical trials
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (NA)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bismuth quadruple therapy CI brief — competitive landscape report
- Bismuth quadruple therapy updates RSS · CI watch RSS
- Zhongda Hospital portfolio CI